Lyell Immunopharma, Inc. (LYEL)
LYEL Stock Price Chart
Explore Lyell Immunopharma, Inc. interactive price chart. Choose custom timeframes to analyze LYEL price movements and trends.
LYEL Company Profile
Discover essential business fundamentals and corporate details for Lyell Immunopharma, Inc. (LYEL) to support your stock research and investment decisions.
Sector
Healthcare
Industry
Biotechnology
IPO Date
17 Jun 2021
Employees
161.00
Website
https://www.lyell.comCEO
Lynn Seely
Description
Lyell Immunopharma, Inc., a clinical-stage cell therapy company, develops chimeric antigen receptor (CAR) T-cell product candidates for patients with hematologic malignancies and solid tumors. The company’s lead product candidate include rondecabtagene autoleucel, an autologous dual-targeting CD19/CD20 CAR T-cell therapy in development, which is in pivotal PiNACLE trial in the 3L+ setting and in a Phase 1/2 clinical trial in the 2L setting, as well as a second pivotal trial, PiNACLE-H2H, which is a Phase 3 head-to-head CAR T cell therapy randomized controlled trial of ronde-cel for LBCL in the 2L setting for the treatment of large B-cell lymphoma; and LYL273, a GCC-targeted CAR T-cell product candidate enhanced with CD19 CAR expression and controlled cytokine release designed to improve CAR T-cell expansion, immune cell infiltration, and cancer cell killing in the hostile solid tumor microenvironment, which is in Phase 1 clinical trial for the treatment of refractory metastatic colorectal cancer. The company develops therapies using various approaches, such as c-Jun overexpression and NR4A3 gene knockout, to endow functional resistance to exhaustion; Epi-R to generate population of stem-like T cells with reduced exhaustion and improved proliferation and antitumor activity; and CD62L positive enrichment to generate CAR T cells with enhanced antitumor activity. Lyell Immunopharma, Inc. was incorporated in 2018 and is headquartered in South San Francisco, California.
LYEL Financial Timeline
Browse a chronological timeline of Lyell Immunopharma, Inc. corporate events including earnings releases, dividend announcements, and stock splits.
Upcoming earnings on 11 Aug 2026
EPS estimate is -$2.03, while revenue estimate is $5.75k.
Earnings released on 6 May 2026
EPS came in at -$1.10 surpassing the estimated -$2.78 by +60.43%, while revenue for the quarter reached $2.00k , missing expectations by -33.33%.
Earnings released on 12 Mar 2026
EPS came in at -$7.68 falling short of the estimated -$2.15 by -257.21%, while revenue for the quarter reached $6.00k , missing expectations by -60.66%.
Earnings released on 12 Nov 2025
EPS came in at -$2.13 surpassing the estimated -$2.81 by +24.20%, while revenue for the quarter reached $15.00k .
Earnings released on 12 Aug 2025
EPS came in at -$2.89 surpassing the estimated -$3.80 by +23.95%, while revenue for the quarter reached $8.00k , beating expectations by +100.00%.
Stock split effective on 2 Jun 2025
Shares were split 1 : 20 , changing the number of shares outstanding and the price per share accordingly.
Earnings released on 13 May 2025
EPS came in at -$3.60 surpassing the estimated -$3.80 by +5.26%, while revenue for the quarter reached $7.00k .
Earnings released on 11 Mar 2025
EPS came in at -$0.72 falling short of the estimated -$0.18 by -300.00%, while revenue for the quarter reached $11.00k .
Earnings released on 7 Nov 2024
EPS came in at -$0.17 surpassing the estimated -$0.20 by +15.00%, while revenue for the quarter reached $34.00k .
Earnings released on 7 Aug 2024
EPS came in at -$0.18 surpassing the estimated -$0.20 by +10.00%, while revenue for the quarter reached $13.00k , beating expectations by +300.00%.
Earnings released on 6 May 2024
EPS came in at -$0.24 falling short of the estimated -$0.20 by -20.00%, while revenue for the quarter reached $3.00k , beating expectations by +200.00%.
Earnings released on 28 Feb 2024
EPS came in at -$0.20 surpassing the estimated -$0.21 by +4.76%, while revenue for the quarter reached $13.00k , beating expectations by +300.00%.
Earnings released on 7 Nov 2023
EPS came in at -$0.20 surpassing the estimated -$0.27 by +25.93%, while revenue for the quarter reached $25.00k , beating expectations by +300.00%.
Earnings released on 8 Aug 2023
EPS came in at -$0.26 surpassing the estimated -$0.30 by +13.33%, while revenue for the quarter reached $27.00k , beating expectations by +50.00%.
Earnings released on 4 May 2023
EPS came in at -$0.27 surpassing the estimated -$0.28 by +3.57%, while revenue for the quarter reached $65.00k , beating expectations by +471.43%.
Earnings released on 28 Feb 2023
EPS came in at -$0.03 surpassing the estimated -$0.31 by +90.32%, while revenue for the quarter reached $48.39k , missing expectations by -99.70%.
Earnings released on 8 Nov 2022
EPS came in at -$0.28 surpassing the estimated -$0.34 by +17.65%, while revenue for the quarter reached $3.00k , missing expectations by -99.83%.
Earnings released on 4 Aug 2022
EPS came in at -$0.15 surpassing the estimated -$0.31 by +51.61%, while revenue for the quarter reached $35.74m , beating expectations by +100.00%.
Earnings released on 10 May 2022
EPS came in at -$0.28 surpassing the estimated -$0.29 by +3.45%, while revenue for the quarter reached $553.00k , missing expectations by -28.78%.
Earnings released on 29 Mar 2022
EPS came in at -$0.18 surpassing the estimated -$0.28 by +35.71%, while revenue for the quarter reached $2.82m , beating expectations by +6.79%.
Earnings released on 12 Nov 2021
EPS came in at -$0.20 surpassing the estimated -$0.27 by +25.93%, while revenue for the quarter reached $2.76m , missing expectations by -20.59%.
Earnings released on 12 Aug 2021
EPS came in at -$0.89 falling short of the estimated -$0.36 by -147.22%, while revenue for the quarter reached $2.63m , meeting expectations.
LYEL Stock Performance
Access detailed LYEL performance analysis with candlestick charts, real‑time intraday data and historical financial metrics for comprehensive insights.
Explore Related Stocks
Compare companies within the same sector by viewing performance, key financials, and market trends. Select a symbol to access the full profile.
